Insulin analogues display atypical differentiative activities in skin keratinocytes

References

• Badrick E, Renehan AG. (2014). Diabetes and cancer: 5 years into the recent controversy. Eur J Cancer, 50:2119–25
   PubMed Web of Science ®Google Scholar
• Carstensen B. (2012). Request for clarification from Ruiter et al. regarding “Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: Results from a large population-based follow-up study”. Diabetologia, 55:857–8
   PubMed Web of Science ®Google Scholar
• Hemkens LG, Grouven U, Bender R, et al. (2009). Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia, 52:1732–44
   PubMed Web of Science ®Google Scholar
• Hirsch IB. (2005). Insulin analogues. New England J Med, 352:174–83
   PubMed Web of Science ®Google Scholar
• Jonasson JM, Ljung R, Talback M, et al. (2009). Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia, 52:1745–54
   PubMed Web of Science ®Google Scholar
• Kostev K. (2012). Risk of breast cancer in patients on long-acting insulin analogues in comparison with those on human insulin. Diabetologia, 55:1554–5
   PubMed Web of Science ®Google Scholar
• LeRoith D, Roberts CT Jr. (2003). The insulin-like growth factor system and cancer. Cancer Lett, 195:127–37
   PubMed Web of Science ®Google Scholar
• Mayer D, Chantelau E. (2010). Treatment with insulin glargine (Lantus) increases the proliferative potency of the serum of patients with type-1 diabetes: A pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem, 116:73–8
   PubMedGoogle Scholar
• Nagel JM, Mansmann U, Wegscheider K, Rohmel J. (2010). Insulin resistance and increased risk for malignant neoplasms: Confounding of the data on insulin glargine. Diabetologia, 53:206–8
   PubMed Web of Science ®Google Scholar
• Owens DR, Zinman B, Bolli GB. (2001). Insulins today and beyond. Lancet, 358:739–46
   PubMed Web of Science ®Google Scholar
• Pan J, Chen C, Jin Y, et al. (2012). Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle, 11:2314–26
   PubMed Web of Science ®Google Scholar
• Pollak M, Russell-Jones D. (2010). Insulin analogues and cancer risk: Cause for concern or cause celebre? Int J Clin Pract, 64:628–36
   PubMed Web of Science ®Google Scholar
• Renehan AG. (2012). Insulin analogues and cancer risk: The emergence of second-generation studies. Diabetologia, 55:7–9
   PubMed Web of Science ®Google Scholar
• Ruiter R, Visser LE, van Herk-Sukel MP, et al. (2012). Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: Results from a large population-based follow-up study. Diabetologia, 55:51–62
   PubMed Web of Science ®Google Scholar
• Sadagurski M, Yakar S, Weingarten G, et al. (2006). Insulin-like growth factor 1 receptor signaling regulates skin development and inhibits skin keratinocyte differentiation. Mol Cell Biol, 26:2675–87
   PubMed Web of Science ®Google Scholar
• Slieker LJ, Brooke GS, DiMarchi RD, et al. (1997). Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia, 40:S54–61
   PubMed Web of Science ®Google Scholar
• Smith U, Gale EA. (2009). Does diabetes therapy influence the risk of cancer? Diabetologia, 52:1699–708
   PubMed Web of Science ®Google Scholar
• Sommerfeld MR, Muller G, Tschank G, et al. (2010). In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites. PloS one, 5:e9540
   PubMed Web of Science ®Google Scholar
• Thomson GA. (2010). Insulin, insulin analogues and cancer: No cause for panic. Int J Clin Pract, 64:525–7
   PubMed Web of Science ®Google Scholar
• Vajo Z, Fawcett J, Duckworth WC. (2001). Recombinant DNA technology in the treatment of diabetes: Insulin analogs. Endocrine Rev, 22:706–17
   PubMed Web of Science ®Google Scholar
• Varewijck AJ, Janssen JA. (2012). Insulin and its analogues and their affinities for the IGF1 receptor. Endocrine Related Cancer, 19:F63–75
   PubMed Web of Science ®Google Scholar
• Weinstein D, Simon M, Yehezkel E, et al. (2009). Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes/Met Res Rev, 25:41–9
   PubMed Web of Science ®Google Scholar
• Wertheimer E. (2004). Diabetic skin complications: A need for reorganizing the categories of diabetes-associated complications. Israel Med Assoc J, 6:287–9
   PubMed Web of Science ®Google Scholar
• Wertheimer E, Spravchikov N, Trebicz M, et al. (2001). The regulation of skin proliferation and differentiation in the IR null mouse: Implications for skin complications of diabetes. Endocrinology, 142:1234–41
   PubMed Web of Science ®Google Scholar
• Yehezkel E, Weinstein D, Simon M, et al. (2010). Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor. Diabetologia, 53:2667–75
   PubMed Web of Science ®Google Scholar
• Yuspa SH, Kilkenny AE, Steinert PM, Roop DR. (1989). Expression of murine epidermal differentiation markers is tightly regulated by restricted extracellular calcium concentrations in vitro. J Cell Biol, 109:1207–17
   PubMed Web of Science ®Google Scholar